Dan Vogl, MD, MSCE, director, Abramson Cancer Center Clinical Research Unit (CRU), associate professor of medicine, Hospital of the University of Pennsylvania, Penn Medicine, discusses the utilization of modakafusp alfa (TAK-573) in relapsed/refractory multiple myeloma.

The results of a first-in-human phase 1 study (NCT03215030), which were presented during the 2021 ASH Annual Meeting and Exposition, observing the use of modakafusp alfa in patients with relapsed/refractory multiple myeloma looked encouraging, Vogl says. In addition to showing that modakafusp alfa was well tolerated, responses were observed in in 38% of evaluable patients, Vogl explains. The population includedpatients previously refractory to CD38-directed antibodies, such as daratumumab (Darzalex) and isatuximab-irfc (Sarclisa), Vogl adds.

Moreover, this population included patients with high-risk multiple myeloma, as well as patients who were previously treated with BCMA-directed therapy, Vogl concludes.

Videos

Dan Vogl, MD, MSCE, discusses the utilization of modakafusp alfa in relapsed/refractory multiple myeloma. 


Dan Vogl, MD, MSCE

Articles

Dr. Vogl on the Utilization of Modakafusp Alfa in Relapsed/Refractory Multiple Myeloma